NHC
LLY icon

Nicholas Hoffman & Company’s Eli Lilly LLY Stock Holding History

Nicholas Hoffman & Company’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.98M Sell
9,761
-517
-5% -$524K 0.21% 28
2025
Q4 		$11M Sell
10,278
-86
-0.8% -$82.2K 0.26% 24
2025
Q3 		$7.91M Buy
10,364
+155
+2% +$115K 0.19% 29
2025
Q2 		$7.96M Buy
10,209
+503
+5% +$391K 0.21% 26
2025
Q1 		$8.02M Buy
9,706
+77
+0.8% +$64.1K 0.3% 22
2024
Q4 		$7.43M Sell
9,629
-590
-6% -$489K 0.3% 24
2024
Q3 		$9.05M Sell
10,219
-1,661
-14% -$1.49M 0.38% 22
2024
Q2 		$10.8M Sell
11,880
-147
-1% -$118K 0.5% 18
2024
Q1 		$9.36M Sell
12,027
-235
-2% -$167K 0.47% 20
2023
Q4 		$7.15M Sell
12,262
-86
-0.7% -$50.2K 0.43% 22
2023
Q3 		$6.63M Sell
12,348
-3,358
-21% -$1.73M 0.49% 21
2023
Q2 		$7.37M Buy
15,706
+608
+4% +$255K 0.29% 21
2023
Q1 		$5.19M Buy
15,098
+67
+0.4% +$22.6K 0.47% 25
2022
Q4 		$5.5M Buy
15,031
+34
+0.2% +$12.1K 0.59% 24
2022
Q3 		$4.85M Sell
14,997
-405
-3% -$128K 0.23% 24
2022
Q2 		$4.99M Buy
15,402
+1,886
+14% +$566K 0.23% 23
2022
Q1 		$3.87M Sell
13,516
-546
-4% -$141K 0.15% 28
2021
Q4 		$3.88M Buy
14,062
+24
+0.2% +$6.08K 0.12% 28
2021
Q3 		$3.24M Sell
14,038
-721
-5% -$178K 0.57% 30
2021
Q2 		$3.39M Buy
14,759
+504
+4% +$101K 0.61% 26
2021
Q1 		$2.66M Buy
14,255
+293
+2% +$57.3K 0.54% 31
2020
Q4 		$2.36M Buy
13,962
+91
+0.7% +$13.6K 0.54% 31
2020
Q3 		$2.05M Buy
13,871
+300
+2% +$46.4K 0.54% 29
2020
Q2 		$2.23M Buy
13,571
+43
+0.3% +$6.6K 0.64% 26
2020
Q1 		$1.88M Sell
13,528
-9
-0.1% -$1.24K 0.63% 32
2019
Q4 		$1.78M Sell
13,537
-501
-4% -$58.1K 0.49% 44
2019
Q3 		$1.57M Sell
14,038
-303
-2% -$33.7K 0.48% 50
2019
Q2 		$1.59M Sell
14,341
-1,283
-8% -$151K 0.49% 47
2019
Q1 		$2.03M Buy
15,624
+2,053
+15% +$250K 0.65% 35
2018
Q4 		$1.57M Sell
13,571
-254
-2% -$28.4K 0.54% 42
2018
Q3 		$1.48M Buy
13,825
+2,001
+17% +$200K 0.5% 44
2018
Q2 		$1.01M Sell
11,824
-828
-7% -$68K 0.37% 67
2018
Q1 		$979K Sell
12,652
-23
-0.2% -$1.85K 0.38% 69
2017
Q4 		$1.07M Hold
12,675
– – 0.42% 62
2017
Q3 		$1.08M Buy
12,675
+1
+0% +$82 0.46% 59
2017
Q2 		$1.04M Buy
12,674
+251
+2% +$20.5K 0.47% 58
2017
Q1 		$1.04M Sell
12,423
-62
-0.5% -$4.97K 0.49% 58
2016
Q4 		$931K Sell
12,485
-67
-0.5% -$4.99K 0.47% 57
2016
Q3 		$1.01M Buy
12,552
+152
+1% +$12.2K 0.55% 47
2016
Q2 		$977K Buy
+12,400
New +$934K 0.57% 48

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nicholas Hoffman & Company's LLY Position: Q1 2026 in Review

Nicholas Hoffman & Company reduced its Eli Lilly (LLY) stake by 5% in Q1 2026, selling an estimated $524K and leaving 9,761 shares worth $8.98M. The position accounts for 0.21% of the portfolio, ranked #28.

Nicholas Hoffman & Company first reported a position in LLY in Q2 2016 and has held it in 40 quarters since. The position peaked at $11M in Q4 2025. 4,356 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Nicholas Hoffman & Company held 9,761 shares of Eli Lilly worth $8.98M as of Q1 2026.
  • Nicholas Hoffman & Company sold 517 Eli Lilly shares in Q1 2026, an estimated $524K.
  • Eli Lilly made up 0.21% of Nicholas Hoffman & Company's portfolio in Q1 2026, its #28 holding.
  • Nicholas Hoffman & Company first reported a position in Eli Lilly in Q2 2016 and has held it in 40 quarters since.
  • Nicholas Hoffman & Company's Eli Lilly position peaked at $11M in Q4 2025.
  • 4,356 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q1 2026, filed 29 Apr 2026.